Affiliation:
1. Central Research Institute of Epidemiology Federal service for supervision in the field of protection of the rights of consumers and well-being man’s
Abstract
Aim: to analyze the prevalence, structure of drug resistance and drug resistance mutations in the protease and reverse transcriptase genes of HIV-1 among treatment naïve patients.Materials and methods. We analyzed protease and reverse transcriptase sequences from 1560 treatment naïve HIV-infected patients from all Federal Districts of the Russian Federation with the first positive immune blot during 1998–2017. Sequences were analyzed for the presence of drug resistance mutations and predicted drug resistance to antiretroviral drugs using two algorithms — Stanford HIVDR Database (HIVdb) and the 2009 SDRM list (CPR).Results. The prevalence of drug resistance mutations was 11,1%. More often the prevalence of drug resistance was found for non-nucleoside reverse transcriptase inhibitor drugs (rilpivirine, nevirapine, efavirenz). The prevalence of transmitted drug resistance associated with mutations from the SDRM list was 5,3%, which is classified by the WHO as a moderate level. However, it should be noted that since the large-scale use of antiretroviral drugs in the Russian Federation, there has been a trend towards a gradual increase in the level of the transmitted drug resistance, and in 2016 it has already reached 6,1%.Conclusion. The results demonstrate the need for regular surveillance of the prevalence of HIV drug resistance to antiretroviral drugs among treatment naïve patients in the Russian Federation.
Publisher
Baltic Medical Education Center
Subject
Infectious Diseases,Public Health, Environmental and Occupational Health,Immunology
Reference14 articles.
1. Joint United Nations Programme (UNAIDS). 90-90-90 An ambitious treatment target to help end the AIDS epidemic. Geneva, 2014, 33 p. URL: http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf (October 2014).
2. Guidelines on the public health response to pretreatment HIV drug resistance. Geneva: World Health Organization, 2017, 84 p. URL: https://apps.who.int/iris/bitstream/handle/10665/255880/9789241550055-eng.pdf?sequence=1 (July 2017).
3. WHO/HIVResNet HIV drug resistance laboratory operational framework. Geneva: World Health Organization, 2017, 73 p. URL: https://apps.who.int/iris/bitstream/handle/10665/259731/9789241512879-eng.pdf?sequence=1 (December 2017).
4. Fokam J., Takou D., Santoro M.M., Akonie H.Z., Kouanfack C., Ceccherini-Silberstein F., Colizzi V. et al. Population-based surveillance of HIV- 1 drug resistance in Cameroonian adults initiating antireviral therapy according to the World Health Organization guidelines. AIDS Res. Hum. Retrovir., 2016, Vol. 32, No. 4, pp. 329–333.
5. Quinn T.C. HIV epidemiology and the effects of antiviral therapy on long-term consequences. AIDS, 2008, Vol. 22, Suppl. 3, pp. S7–S12.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献